Zobrazeno 1 - 10
of 19
pro vyhledávání: '"35"'
Autor:
Christopher Sweeney, Eric Winquist, Darren R. Feldman, Ugo De Giorgi, Daniel Y.C. Heng, Silke Gillessen, Michal Chovanec, Jourik A. Gietema, Robert Huddart, Costantine Albany, Fay H. Cafferty, Peter Grimison, Aaron R. Hansen, Carsten Bokemeyer, Karim Fizazi, Jörg Beyer, Christian D. Fankhauser, Nicolas Sauvé, Alexey Tryakin, Torgrim Tandstad, Olof Ståhl, Helene F. S. Negaard, Ronald de Wit, Anja Lorch, Andrea Necchi, David J. Vaughn, Angelika Terbuch, Axel Heidenreich, Cora N. Sternberg, Marcus Hentrich, Xavier Garcia-del-Muro, Gedske Daugaard, Laurence Collette, Jonathan Shamash
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
J Clin Oncol
Gillessen, Silke; Sauvé, Nicolas; Collette, Laurence; Daugaard, Gedske; de Wit, Ronald; Albany, Costantine; Tryakin, Alexey; Fizazi, Karim; Stahl, Olof; Gietema, Jourik A; De Giorgi, Ugo; Cafferty, Fay H; Hansen, Aaron R; Tandstad, Torgrim; Huddart, Robert A; Necchi, Andrea; Sweeney, Christopher J; Garcia-Del-Muro, Xavier; Heng, Daniel Y C; Lorch, Anja; ... (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), pp. 1563-1574. 10.1200/JCO.20.03296
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), 1563-+. AMER SOC CLINICAL ONCOLOGY
Universidad de Barcelona
J Clin Oncol
Gillessen, Silke; Sauvé, Nicolas; Collette, Laurence; Daugaard, Gedske; de Wit, Ronald; Albany, Costantine; Tryakin, Alexey; Fizazi, Karim; Stahl, Olof; Gietema, Jourik A; De Giorgi, Ugo; Cafferty, Fay H; Hansen, Aaron R; Tandstad, Torgrim; Huddart, Robert A; Necchi, Andrea; Sweeney, Christopher J; Garcia-Del-Muro, Xavier; Heng, Daniel Y C; Lorch, Anja; ... (2021). Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), pp. 1563-1574. 10.1200/JCO.20.03296
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(14), 1563-+. AMER SOC CLINICAL ONCOLOGY
PURPOSE The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990. MATERIALS AND METHODS Da
Autor:
Apurvasena Parikh, Colin D. Weekes, Monica Motwani, Daniel Morgensztern, Huibin Yue, Edward B. Reilly, John Nemunaitis, Todd M. Bauer, Ramesh K. Ramanathan, Daniel E. H. Afar, Rebecca S. Heist, Karen Kelly, Eric Angevin, John H. Strickler, Louie Naumovski
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 33
Strickler, JH; Weekes, CD; Nemunaitis, J; Ramanathan, RK; Heist, RS; Morgensztern, D; et al.(2018). First-in-Human Phase I, Dose-Escalation and-Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018787697. doi: 10.1200/jco.2018.78.7697. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bt41691
Strickler, JH; Weekes, CD; Nemunaitis, J; Ramanathan, RK; Heist, RS; Morgensztern, D; et al.(2018). First-in-Human Phase I, Dose-Escalation and-Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018787697. doi: 10.1200/jco.2018.78.7697. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bt41691
Purpose This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody–drug conjugate of the anti–c-Met monoclonal antibody ABT-700 and monomethyl auristatin E. Materials and Methods For dose escalatio
Autor:
Masato Nakamura, Masahito Kotaka, Yasutoshi Kuboki, Eiji Oki, Takayuki Yoshino, Jun Watanabe, Tetsuji Terazawa, Takashi Ohta, Hitoshi Ojima, Hiroki Hara, Yu Sunakawa, Soichiro Ishihara, Hiroya Taniguchi, Takako Eguchi Nakajima, Kuniaki Shirao, Yudai Shinohara, Toshiki Masuishi, Satoshi Morita
Publikováno v:
Journal of Clinical Oncology. 39:3507-3507
3507 Background: The efficacy of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) as a later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated in clinical trials. Therefore, we conducted a randomized phase 2/3 study
Autor:
Rohan Garje, Ryan Reis, Maheen Rajput, Umang Swami, Youcef M. Rustum, Janelle M Born, Andrew M. Bellizzi, Jessica C. Sieren, Bashar Abuqayas, Kenneth G. Nepple, Yousef Zakharia, James A. Brown
Publikováno v:
Journal of Clinical Oncology. 39:322-322
322 Background: Hypoxia induced factor 1α/2α (HIFs) and vascular endothelial growth factor (VEGF) are overexpressed in ccRCC and associated with increased tumor angiogenesis, vascular instability and drug resistance. In xenografts, high dose SLM re
Autor:
Enrique Gallardo Diaz, Sergio Vazquez-Estevez, Maria Piedad Fernandez Perez, Begoña Mellado, Ignacio Duran, Enrique Gonzalez-Billalabeitia, Miguel Angel Climent, Aranzazu Gonzalez del Alba, Carmen Santander, M.J. Méndez-Vidal, M Isabel Sáez, Ovidio Fernandez Calvo, Angel Sánchez, Enrique Grande, Javier Puente, Elena Castro, Gerhardt Attard, Daniel Wetterskog, Albert Font Pous, Daniel Castellano
Publikováno v:
Journal of Clinical Oncology. 37:5040-5040
5040 Background: TMPRSS2-ERG fusion gene is a common driver of prostate cancer. The PREMIERE study is a phase II, single arm open-label, multicentre, clinical trial designed to analyse the predictive/prognostic value of TMPRSS2-ERG in first-line chem
Autor:
Masahito Kotaka, Hirofumi Kawanaka, Akira Kabashima, Mototsugu Shimokawa, Akitaka Makiyama, Tomomi Kashiwada, Masahiro Hamanoue, Hideo Baba, Keisuke Miwa, Masaki Mori, Eiji Oki, Yuji Miyamoto, Hiroshi Saeki, Yoshito Akagi, Takafumi Ohchi
Publikováno v:
Journal of Clinical Oncology. 37:3548-3548
3548 Background: Elderly patients are often intolerable in combination of cytotoxic agents. Recently, Trifluridine/tipiracil plus bevacizumab has been shown as good candidate for the vulnerable patients. We aimed to assess the efficacy and safety of
Autor:
Alessandra Tedeschi, Davide Rossi, Emanuele Zucca, Stefano Pileri, Marco Montillo, Franco Cavalli, Anna Maria Frustaci
Publikováno v:
Journal of Clinical Oncology. 37:TPS7575-TPS7575
TPS7575 Background: Diffuse large B-cell (DLBCL) transformation from chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Richter Syndrome (RS), has poor prognosis. Venetoclax, Bcl-2 inhibitor, has shown activity either in DLBCL an
Autor:
William C. Wood, Fengmin Zhao, Vicky Jones, Silvana Martino, Nancy E. Davidson, Vered Stearns, Molin Wang, Tom Saphner, George W. Sledge, Joseph A. Sparano, Edith A. Perez, Bryan P. Schneider, Antonio C. Wolff
Publikováno v:
Journal of Clinical Oncology. 30:3051-3057
Purpose Neuropathy is a common and potentially disabling complication of adjuvant taxane therapy. Recent studies have identified candidate single nucleotide polymorphisms associated with taxane-induced neuropathy. Therefore, we sought to determine wh
Autor:
Moacyr Ribeiro de Oliveira, D. Ross Camidge, Elizabeth Litvinovich, Yi-Lin Chiu, Cathy E. Nolan, Charles M. Rudin, Divis Khaira, Geoffrey I. Shapiro, Todd A. Busman, Hao Xiong, Caroline Dive, David R. Gandara, Evelyn McKeegan, Philip Bonomi, Sari H. Enschede, Rod A. Humerickhouse, Andrew Krivoshik, Leena Gandhi, Philip M. Hemken, Christine L. Hann
Publikováno v:
Journal of Clinical Oncology. 29:909-916
Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel in
Autor:
Jianwei Yang, Xiaoyan Lin, Feng Ye, Xiang-Yuan Wu, Guifang Zhang, Wenying Deng, Jin Li, Haijun Zhong, Yuxian Bai, Junsheng Wang, Yi Ba, Likun Liu, Min Tao, Lu Wen, Tongfu Jia, Congying Xie, Lin Wang, Yifu He, Mei Wang, Shukui Qin
Publikováno v:
Journal of Clinical Oncology. 36:35-35
35 Background: A fine balance between maintaining efficacy and reducing toxicity is necessary for drug therapies in many cancers. This study seeks to review the data from phase IV clinical trial of Ahead-G201 to help elucidate the optimal initial dos